Browsing by Author "Jothydev Kesavadev"

Now showing 1 - 2 of 2

Evidence-based recommendations for insulin intensification strategies after basal insulin in type 2 diabetes
(Elsevier Ltd, 2017) Sujoy Ghosh; A.G. Unnikrishnan; Banshi Saboo; Jothydev Kesavadev; S.R. Aravind; Sarita Bajaj; Rajesh Rajput; Krishna Seshadri; Narsingh Verma; Arvind Gupta; Brij Mohan Makkar; Mihir Saikia; Shailaja Kale; Suresh Damodaran; Ashish Dengra; T.K.M. Eashwar; Anuj Maheshwari; Sharad Pendsey; Sanjeev R. Phatak; Surendra Kumar Sharma; Surya Kumar Singh; A. Ramachandran; Abdul H. Zargar; Shashank R. Joshi; Shaukat M. Sadikot
Over the time due to progressive nature of diabetes, proactive intensification of the existing insulin therapy becomes imminent as it minimizes patients’ exposure to chronic hypo/hyperglycaemia and reduces weight gain while achieving individualized glycaemic targets. This review focuses on the strength of evidence behind various options for intensification, primarily the insulins as also the GLP-1 analogues. The recommendations presented here are meant to serve as a guide for the physician managing type 2 diabetes patients requiring insulin intensification upon failing of basal insulin therapy. © 2017 Diabetes India
Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades
(Bentham Science Publishers, 2024) Banshi Saboo; Hemraj Chandalia; Sujoy Ghosh; Jothydev Kesavadev; I.P.S. Kochar; K.M. Prasannakumar; Archana Sarda; Ganapathi Bantwal; R.N. Mehrotra; Madhukar Rai
Background: Over the past two decades, insulin glargine 100 U/mL (Gla-100) has emerged as the “standard of care” basal insulin for the management of type 1 diabetes mellitus (T1DM). Both formulations, insulin glargine 100 U/mL (Gla-100) and glargine 300 U/mL (Gla300) have been extensively studied against various comparator basal insulins across various clinical and real-world studies. In this comprehensive article, we reviewed the evidence on both insulin glargine formulations in T1DM across clinical trials and real-world studies. Methods: Evidence in T1DM for Gla-100 and Gla-300 since their approvals in 2000 and 2015, respectively, were reviewed. Results: Gla-100 when compared to the second-generation basal insulins, Gla-300 and IDeg-100, demonstrated a comparable risk of overall hypoglycemia, but the risk of nocturnal hypoglycemia was higher with Gla-100. Additional benefits of Gla-300 over Gla-100 include a prolonged (>24hours) duration of action, a more stable glucose-lowering profile, improved treatment satisfaction, and greater flexibility in the dose administration timing. Conclusion: Both glargine formulations are largely comparable to other basal insulins in terms of glucose-lowering properties in T1DM. Further, risk of hypoglycemia is lower with Gla-100 than Neutral Protamine Hagedorn but comparable to insulin detemir. © 2024 Bentham Science Publishers.